Related Experiment Video
Updated: Jun 29, 2025
11:12
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
8.0K
Neuroendocrine breast carcinoma
Laura Pratas Guerra1, Joana Simões1, Diogo Carvalho Sá2
1Unidade Local de Saúde de Santo António, Serviço de Oncologia Médica, Porto, Portugal.
Autopsy & Case Reports
|April 2, 2024
Summary
Neuroendocrine breast cancer (NEBC) is rare. A case study shows successful radical treatment, including chemotherapy, surgery, and endocrine therapy with a CDK4/6 inhibitor, for oligometastatic disease.
Area of Science:
- Oncology
- Endocrinology
- Pathology
Background:
- Neuroendocrine breast cancer (NEBC) is a rare and heterogeneous malignancy.
- It often presents with a luminal phenotype and carries a poorer prognosis.
- Differential diagnosis in advanced stages must exclude metastasis from other neuroendocrine tumors.
Observation:
- A premenopausal woman presented with oligometastatic large cell neuroendocrine carcinoma of the breast.
- The tumor was estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative.
- The patient was highly symptomatic at diagnosis.
Findings:
- Initial chemotherapy led to a complete radiological response of metastatic disease.
- Subsequent radical treatment included breast surgery, bilateral oophorectomy, and radiation therapy.
- Current treatment involves endocrine therapy (ET) and a CDK4/6 inhibitor (CDK4/6i), with no evidence of disease recurrence.
Implications:
- Evidence for NEBC treatment is limited, underscoring the need for more research.
- Radical treatment approaches should be considered for oligometastatic NEBC.
- Encouraging the reporting of rare NEBC cases is crucial for advancing understanding and treatment strategies.
